Novo Nordisk A/S (NYSE:NVO) gapped up before the market opened on Thursday . The stock had previously closed at $53.65, but opened at $53.82. Novo Nordisk A/S shares last traded at $54.12, with a volume of 754,739 shares trading hands.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $63.00 price target for the company in a report on Tuesday, May 3rd. Citigroup Inc. restated a “buy” rating on shares of Novo Nordisk A/S in a report on Friday, April 1st. Finally, Goldman Sachs Group Inc. cut shares of Novo Nordisk A/S from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, June 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $61.00.

The firm’s 50 day moving average is $54.18 and its 200-day moving average is $54.42. The company has a market capitalization of $138.82 billion and a price-to-earnings ratio of 27.32.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Friday, April 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.04. On average, equities analysts forecast that Novo Nordisk A/S will post $2.27 EPS for the current year.

A number of large investors have modified their holdings of NVO. Alpha Cubed Investments LLC raised its stake in shares of Novo Nordisk A/S by 8.9% in the fourth quarter. Alpha Cubed Investments LLC now owns 17,419 shares of the company’s stock valued at $1,012,000 after buying an additional 1,424 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Novo Nordisk A/S by 5.6% in the fourth quarter. Rhumbline Advisers now owns 20,800 shares of the company’s stock valued at $1,208,000 after buying an additional 1,100 shares during the last quarter. Bangor Savings Bank raised its stake in shares of Novo Nordisk A/S by 0.3% in the fourth quarter. Bangor Savings Bank now owns 25,921 shares of the company’s stock valued at $1,505,000 after buying an additional 74 shares during the last quarter. Hansberger Growth Investors LP raised its stake in shares of Novo Nordisk A/S by 3.0% in the fourth quarter. Hansberger Growth Investors LP now owns 29,312 shares of the company’s stock valued at $1,702,000 after buying an additional 866 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $1,718,000.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.